Pfizer said that its experimental rheumatoid arthritis drug met the main goals of a late-stage clinical trial, a welcome boost for the world's largest drugmaker as it seeks new products to offset those that are losing patent protection.
49489
Pfizer arthritis drug meets main goals of trial
26795
Benefits of some cancer drugs exaggerated because trials were stopped early
124569
BioAlliance Pharma announces the
75564
Pfizer pays out to doctors, researchers
115795
Researchers identify new drug target for heart failure
146221
The clinical trials market in Poland is growing, but at a moderate pace
175596
Compugen discovers cancer treatment target
38108
Drug for bones helps keep breast cancer from spreading
156830
Boston Scientific PREVAIL trial meets two out of three co-primary endpoints
128394
Two new drugs can slash stroke risk
56284
Researchers call for more public disclosure about clinical drug trials
79488
RB Milestone initiates coverage of ProMetic
75625
Genzyme faces production delays for key drugs
29805
Rheumatoid arthritis rising in women
71114
Anakinra is relatively safe, modestly effective in rheumatoid arthritis
63912
Breakthrough could nip arthritis in the bud
84817
Merck KGaA's Erbitux drug extends survival for some